- Monoclonal Antibody
- Fusion Proteins
Immunological Rare Disease Market size is poised to grow at a significant CAGR of 11.9% over 2023-2029. The immune system is delegated to defend the body from attacks from outside or inside. Many diseases can affect the immune system reducing its ability to defend itself or inducing an abnormal response against external or internal antigens. Immunological Rare diseases, often known as orphan diseases, afflict a small percentage of the population at any given time. Orphan medications are those that are suggested for the treatment of rare disorders. An orphan immunological disease is one that affects less than 200,000 persons in the United States, according to the Food and Drug Administration (FDA). Furthermore, Several diseases can affect the immune system. Disorders associated with a reduced response against no self-antigens are called immunodeficiencies. On the other hand, primary immunodeficiencies (PIDs) are in most cases rare diseases associated with specific, genetic mutations. Immunology medications or substances modify immune responses by enhancing or inhibiting the immune system. They are used to fight infections as well as to prevent or cure autoimmune or immunological illnesses such as rheumatoid arthritis, psoriatic arthritis, type 1 diabetes, and others. Rising awareness about rare immunological diseases such as Hypoalbuminemia and Hypovolemia, and Severe Congenital Protein C Deficiency in both developing and developed nations and the rising occurrence of immunological disorders due to environmental factors are critical reasons for increasing the demand for rear immunological drugs in the market. For instance, According to the Centers for Disease Control and Prevention's (CDC) 2020 National Diabetes Statistics report, the incidence of type 1 diabetes in the United States increased by 30% between 2017 and 2020. In 2017, there were 1.25 million people, which is expected to rise to 1.6 million by 2020.
Immunological Rare Disease Market Key Developments:
In May 2022, Pfizer Inc. strengthened its product portfolio by acquiring Arena Pharmaceuticals, a business that discovers revolutionary potential treatments for the treatment of many immuno-inflammatory diseases.
Fastest Growing Market
A variety of variables, including hazardous chemical exposure, stress, dietary components, gut dysbiosis, and infections, all contribute to an increase in the number of persons suffering from rear immunological disorders. Immunological rare disease problems are now the most common cause of chronic illness in the United States, with a considerable number of individuals suffering from at least one form of rear immunological disease. For instance, according to a study published by the National Stem Cell Foundation, roughly 4% of the world's population is afflicted with at least one of 80 or more with Immunological rear diseases. The rising demand for these treatments among the patient population is pushing industry participants' aggressive attempts to develop and introduce new pharmaceuticals into the market. As a result, the pipeline portfolio of leading immunology companies is expanding dramatically. For instance, there are around 30 pipeline projects of Sanofi in the immunology segment and around 20 pipeline candidates of Johnson & Johnson Services.
Key factors that are driving the immunological rare disease market are the rising prevalence of autoimmune disorders and increasing novel therapies.
North American region dominated the immunological rare disease market with a highest revenue share in the 2022 owing the region's well-developed healthcare infrastructure.
High Cost of Treatment and Adverse Effects Associated with Product to Restrict Market Growth.
Some of the top players operating in the prebiotics market are AbbVie, Inc. (U.S.), Janssen Global Services, LLC (U.S.), Eli Lilly and Company (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Merck Sharp & Dohme Corp. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen Inc. (U.S.), Astellas Pharma Inc. (Japan), UCB SA (Belgium).